Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico.
Alan Kooi Davis, Yitong Xin, Nathan D. Sepeda, Lynnette A. Averill
The American Journal of Drug and Alcohol Abuse September 3, 2023 DOI: 10.1080/00952990.2023.2220874 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Prospective clinical program evaluation Open-label Peer reviewed |
|---|---|
| Sample size | 86 |
| Population | Trauma-exposed Special Operations Forces Veterans |
| Interventions | Ibogaine 5-MeO-DMT |
| Duration | 6-month follow-up |
| Topics | 5-MeO-DMT Ibogaine DMT |
| Keywords | Psychedelic Special operations veterans Hallucinogenic therapy Entheogenic medicine Veteran PTSD Combat trauma treatment Innovative treatment Non-traditional |
| Citations | 29 |
| Key points | Combined ibogaine and 5-MeO-DMT assisted therapy produced significant and large improvements in PTSD, depression, anxiety, insomnia, and cognitive functioning among Special Operations Forces Veterans, with effects lasting up to six months. |
Abstract
Background: Research in psychedelic medicine has focused primarily on civilian populations. Further study is needed to understand whether these treatments are effective for Veteran populations.Objectives: Here, we examine the effectiveness of psychedelic-assisted therapy among trauma-exposed Special Operations Forces Veterans (SOFV) seeking treatment for cognitive and mental health problems in Mexico.Methods: Data were collected from an ibogaine and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) clinical treatment program for SOFV with a history of trauma exposure. This clinical program collects prospective clinical program evaluation data, such as background characteristics, symptom severity, functioning (e.g., satisfaction with life, posttraumatic stress disorder symptoms, depression symptoms, anxiety symptoms, sleep disturbance, psychological flexibility, disability in functioning, cognitive functioning, neurobehavioral symptoms, anger, suicidal ideation), and substance persisting/enduring effects through online surveys at four timepoints (baseline/pre-treatment, one-, three-, and six-months after treatment).Results: The majority of the sample (n = 86; Mean Age = 42.88, SD = 7.88) were Caucasian (87.2%), non-Hispanic (89.5%), and males (100%). There were significant and large improvements in self-reported PTSD symptoms (p < .001, d = .414), depression (p < .001, d = .275), anxiety (p < .001, d = .276), insomnia severity (p < .001, d = .351), and post-concussive symptoms (p < .001, d = .389) as well as self-reported satisfaction with life (p < .001, d = .371), psychological flexibility (p < .001, d = .313) and cognitive functioning (p < .001, d = .265) from baseline to one-month follow-up.Conclusions: Data suggest combined ibogaine and 5-MeO-DMT assisted therapy has potential to provide rapid and robust changes in mental health functioning with a signal of durable therapeutic effects up to 6-months. Future research in controlled settings is warranted.